converting between glp-1 agonists Frontiers Transforming obesity: The advancement of

Description

Okun The New England Journal of Medicines recent publication of a randomized study of a GLP-1 agonist originally designed for diabetes, but applied to Parkinson's disease, has led to a flurry of excitement and to a mountain of questions

(Well come back to this in the genetics section) The following diagram illustrates how proglucagon is cleaved into its various components: Why GLP-1 Is Broken Down So Fast (DPP-4) The GLP-1 hormone has a remarkably short half-life of around 2 minutes

Mistake #3: Only Doing Cardio (Or No Exercise at All) The Problem: "I walk 5 miles a daythat should be enough to stay toned." Reality: While walking is wonderful for overall health, cardio alone doesn't provide sufficient stimulus to preserve muscle during significant caloric restriction

doi: 10.1126/science.adt0548

While the mechanism is not yet proven, there is support for the idea that GLP-1 attenuates the ras homolog gene family, member A (RhoA)/Rho-associated protein kinase (ROCK) signaling pathway, whose activation is known to reduce levels of occludin, claudin-5, and zonula occludens-1 (ZO-1), as well as promote disruption of endothelial tight junctions